Overview

A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.

Status:
Active, not recruiting

Trial end date:
2022-03-31

Target enrollment:

Participant gender:

Summary

The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.

Phase:

Phase 3

Details

Lead Sponsor:

AstraZeneca

Treatments:

Anastrozole
Estradiol
Fulvestrant
Hormones